[Good clinical practices. Point of view of the drug manufacturers].
For the drug manufacturer the introduction in France of a good clinical practices system will encourage the development of the pharmaceutical industry, provided a number of precautions are observed. These precautions, which include the need for one set of regulations applicable to the whole of Europe and for the training of clinical investigators, are detailed and discussed.